The role of HER2 in metastatic breast cancer treated with a combination of taxanes and cisplatin

Chang Gung Medical Journal

Volumn 32, Issue 1, 2009, Pages 33-41

  Hsu, Hung Chih ^a   Chang, Hsien Kun ^a   Lin, Yung Chang ^a   Hseu, Sheu ^a,b   Chen, Jen Shi ^a   Yang, Tsai Shen ^a   Wang, Hung Ming ^a   Shen, Wen Chi ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Breast cancer; Chemotherapy; Cisplatin; HER2; Taxanes

Indexed keywords

ANTHRACYCLINE; BIOLOGICAL MARKER; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PACLITAXEL; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BONE METASTASIS; BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ASSESSMENT; COMBINATION CHEMOTHERAPY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG RESPONSE; DRUG SENSITIVITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; METASTASIS; MULTIPLE CYCLE TREATMENT; ONCOGENE NEU; OVERALL SURVIVAL; PROGNOSIS; TREATMENT RESPONSE;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; BREAST NEOPLASMS; CISPLATIN; FEMALE; GENES, ERBB-2; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; RETROSPECTIVE STUDIES; TAXOIDS;

EID: 60549097520     PISSN: 20720939     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Hortobagyi GN, Holmes FA. Single agent paclitaxel for the treatment of breast cancer. An overview. Semin Oncol 1999;23(suppl 1):4-9.
2. Pivot X, Asmar L, Hortobagyi GN. The efficacy of chemotherapy with docetaxel and paclitaxel in anthracycline-resistant breast cancer. Int J Oncol 1999;15:381-6.
3. Nabholtz JM, Crown J. Phase III studies of single-agent docetaxel in patients with metastatic breast cancer who have progressed despite previous chemotherapy regimens. Preliminary results. Semin Oncol 1998;25(Suppl 13):4-9.
4. Crown JP. The platinum agents: a role in breast cancer treatment? Semin Oncol 2001;28(Suppl 3):28-37.
5. Zoli W, Flamigni A, Frassineti GL, Bajorko P, De Paola F, Milandri C, Amadori D, Gasperi-Campani A. In vitro activity of taxol and taxotere in comparison with doxorubicin and cisplatin on primary cell cultures of human breast cancers. Breast Cancer Res Treat 1995;34:63-9.
6. Liebmann JE, Fisher J, Teague D, Cook JA. Sequence dependence of paclitaxel (Taxol) combined with cisplatin or alkylators in human cancer cells. Oncol Res 1994;6:25-31.
7. Frasci G, Comella P, D'Aiuto G, Budillon A, Barbarulo D, Thomas R, Capasso I, Casaretti R, Daponte A, Caponigro F, Gravina A, Maiorino L, Carateni G, Gentile A, Comella G. Weekly paclitaxel-cisplatin administration with G-CSF support in advanced breast cancer. A phase II study. Breast Cancer Res Treat 1998;49:13-26.
8. Millward M, Zalcberg J, Bishop J, Webster L, Zimet A, Rischin D, Toner GC , Laird J, Cosolo W, M Urch, Bruno R, Loret C, James R, Blanc C. Phase I trial of docetaxel and cisplatin in previously untreated patients with advanced non-small cell cancer. J Clin Oncol 1997;15:750-8.
9. Wasserheit C, Frazein A, Oratz R, Sorich J, Downey A, Hochster H, Chachoua A, Wernz J, Zeleniuch-Jaccquotte A, Blum R, Speyer J. Phase II trial of paclitaxel and cisplatin in women with advanced breast cancer: an active regimen with limiting neurotoxicity. J Clin Oncol 1996;14:1993-9
10. Maiche AG, Jekunen AP, Kaleva-Kerola J, Blanco SG. High response rate with a lower dose of paclitaxel in combination with cisplatin in heavily pretreated patients with advanced breast carcinoma. Cancer 2000;88:1863-8.
11. Sparano JA, Neuberg D, Glick JH, Robert NJ, Goldstein LJ, Sledge GW, Wood W. Phase II trial of biweekly paclitaxel and cisplatin in advanced breast carcinoma: an Eastern Cooperative Oncology Group study. J Clin Oncol 1997;15:1880-4.
12. Feig LA, Shauffhausen B. The hunt for ras targets. Nature 1994;370:508-9.
13. Gajewski TF, Thompson CB. Apoptosis meets signal transduction: Elimination of a BAD influence. Cell 1996;87:589-92.
14. Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Save-Soderborgh J, Anbazhagan R, Styles J, Rudenstam CM, Golouh R, Reed R. Prognostic Importance of c-erb-B2 expression in breast cancer. J Clin Oncol 1992;10:1049-56.
15. Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, Cirrincione CT, Budman DR, Wood WC, Barcos M, Henderson IC. C-erb-B2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994;330:1260-6.
16. Hamilton A, Piccart M. The contribution of molecular markers to the prediction of response in the treatment of breast cancer: A review of the literature on HER2, p53 and BCL-2. Ann Oncol 2000;1:647-63.
17. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
18. Yu D. Mechanisms of ErbB2-mediated paclitaxel resistance and trastuzumab-mediated paclitaxel sensitization in ErbB2-overexpressing breast cancers. Semin Oncol 2001;28(Suppl 16):12-7.
19. Benz CC, Scott GK, Sarup JC, Johnson RM, Tripathy D, Coronado E, Shepard HM, Osborne CK. Estrogen-dependent tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER-2/neu. Breast Cancer Res Treat 1992;24:85-95.
20. Pietras RJ, Fendly, BM, Chazin VR, Pegram MD, Howell SB, Slamon DJ. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 1994;9:1829-38.
21. Arteaga CL, Winnier AR, Poirier MC, Lopez-Larraza DM, Shawver LK, Hurd SD, Stewart SJ. p185c-erbB-2 signal enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair. Cancer Res 1994;54:3758-65.
22. Pegram MD, Pienkowski T, Northfelt DW, Eiermann W, Patel R, Fumoleau P, Quan E, Crown J, Toppmeyer D, Smylie M, Riva A, Blitz S, Press MF, Reese D, Lindsay MA, Slamon DJ. Results of two open-label multicenter phase II studies of docetaxel, platinum salts and trastuzumab in HER2-positive advanced breast cancer. J Natl Cancer Inst 2004;96:759-69.
23. Hurley J, Doliny P, Reis I, Silva O, Gomez-Fernandez C, Velez P, Pauletti G, Powell JE, Pegram MD, Slamon DJ. Docetaxel, cisplatin and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer. J Clin Oncol 2006;24:1831-8.
24. Gossage L, Madhusudan S. Current status of excision repair cross complementing-group 1 (ERCC1) in cancer. Cancer Treat Rev 2007;33:565-77.
25. Yen L, Woo A, Christopoulopoulos G, Batist G, Panasci L, Roy R, Mitra S, Alaoui-Jamali MA. Enhanced host cell reactivation capacity and expression of DNA repair genes in human breast cancer cells resistant to bi-functional alkylating agents. Mutat Res 1995;337:179-89.
26. Lin YC, Chang HK, Chen JS, Wang HM, Yang TS, Liaw CC. A phase II randomized study of two taxanes and cisplatin for metastatic breast cancer after anthracycline: A final analysis. Jpn J of Clin Oncol 2007;37:23-9.
27. Di Leo A, Chan S, Pasemanas M, Friedrichs K, Pinter T, Cocquyt V, Murray M, Bodrogi I, Walpole E, Lesperance B, Korec S, Crown C, Simmonds P, Minckwitz VG, Leroy JY, Durbecq V, Isola J, Aapro M, Piccart MJ, Larsimont D. HER-2/neu as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel. Breast Cancer Res Treat 2004;86:197-206.
28. Van Poznak C, Tan L, Panageas KS, Arroyo CD, Hudis C, Norton L, Seidman AD. Assessment of molecular markers of clinical sensitivity to single-agent taxane therapy for metastatic breast cancer. J Clin Oncol 2002;20:2319-26.
29. Hamilton A, Larsimont D, Paridaens R, Drijkoningen M, van de Vijver M, Bruning P, Hanby A, Houston S, Treilleux I, Guastalla JP, Van Vreckem A, Sylvester R, Piccart M. A study of the value of p53, HER2, and Bcl-2 in the prediction of response to doxorubicin and paclitaxel as single agents in metastatic breast cancer: a companion study to EORTC 10923. Clin Breast Cancer 2000;1:233-40.
30. Sjostrom J, Collan J, von Boguslawski K, Franssila K, Bengtsson NO, Mjaaland I, Malmstrom P, Ostenstad B, Wist E, Valvere V, Bergh J, Skiold-Petterson D, Saksela E, Blomqvist C. C-erbB-2 expression does not predict response to docetaxel or sequential methotrexate and 5-fluorouracil in advanced breast cancer. Euro J Cancer 2002;38:535-42.
31. Azambuja E, Durbecq V, Rosa D, Colozza M, Larsimont D, Piccart-Gebhart M, Cardoso F. HER-2 overexpression/amplification and its interaction with taxane-based therapy in breast cancer. Ann Oncol 2008;19:223-32.
32. Di Leo A, Gancberg D, Larsimont D, Tanner M, Jarvinen T, Rouas G, Dolci S, Leroy JY, Paesmans M, Isola J, Piccart MJ. HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin Cancer Res 2002;8:1107-16.
33. Kauraniemi P, Barlund M, Monni O, Kallioniemi A. New amplified and highly expressed genes discovered in the ERBB2 amplicon in breast cancer by cDNA microarrays. Cancer Res 2001;61:8235-40.
34. Jarvinen TA, Holli K, Kuukasjarvi T, Isola JJ. Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer. Br J Cancer 1998;77:2267-73.
35. Konecny GE, Thomssen C, Luck HJ, Untch M, Wang HJ, Kuhn W, Eidtmann H, du Bois A, Olbricht S, Steinfeld D, Mobus V, Minckwitz VG, Dandekar S, Ramos L, Pauletti G, Pegram MD, Janicke F, Slamon DJ .HER-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer. J Natl Cancer Institute 2004;96:1141-51.
36. Estevez LG, Cuevas JM, Anton A, Florian J, Lopez-Vega JM, Velasco A, Lobo F, Herrero A, Fortes J. Weekly docetaxel as neoadjuvant chemotherapy for stage II and III breast cancer efficacy and correlation with biological markers in a phase II, multicenter study. Clin Cancer Res 2003;9:686-92.
37. Formenti SC, Spicer D, Skinner K, Cohen D, Groshen S, Bettini A, Naritoku W, Press M, Salonga D, Tsao-Wei D, Danenberg K, Danenberg P. Low HER2/neu gene expression is associated with pathological response to concurrent paclitaxel and radiation therapy in locally advanced breast cancer. Int J Radiat Oncol Biol Phys 2002;52:397-405.
38. Guarneri V, Bengala C, Orlandini C, Gennari A, Donati S, Campani D, Collecchi P, Maur M, Conte PF. HER2 overexpression as a prognostic factor in metastatic breast cancer patients treated with high-dose chemotherapy and autologous stem cell support. Bone Marrow Transplant 2004;34:413-7.